Report cover image

Immune thrombocytopenia (ITP) - Pipeline Insight, 2024

Publisher DelveInsight
Published Apr 01, 2024
Length 80 Pages
SKU # DEL18679659

Description

Immune thrombocytopenia (ITP) - Pipeline Insight, 2024



DelveInsight’s, “Immune thrombocytopenia - Pipeline Insight, 2024,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Immune thrombocytopenia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
  • Global coverage
Immune thrombocytopenia Understanding

Immune thrombocytopenia: Overview

Immune thrombocytopenia (ITP), formerly known as Idiopathic thrombocytopenic purpura is an autoimmune bleeding disorder. The disease is characterized by abnormally low levels of blood cells called platelets. ITP manifests as a bleeding tendency, easy bruising (purpura), or extravasation of blood from capillaries into skin and mucous membranes (petechiae). The diagnosis of ITP is made by excluding other causes of thrombocytopenia along with blood tests. Treatment for ITP is based on goals to prevent bleeding and stabilize as well as improvement in platelet count. Corticosteroid drugs like prednisone, dexamethasone, and methylprednisolone is usually the mainstay of first line therapy. In 2008, the FDA approved Nplate and Promacta to treat both children and adults with ITP who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.

""Immune thrombocytopenia - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Immune thrombocytopenia pipeline landscape is provided which includes the disease overview and Immune thrombocytopenia treatment guidelines. The assessment part of the report embraces, in depth Immune thrombocytopenia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Immune thrombocytopenia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
  • The companies and academics are working to assess challenges and seek opportunities that could influence Immune thrombocytopenia R&D. The therapies under development are focused on novel approaches to treat/improve Immune thrombocytopenia.
Immune thrombocytopenia Emerging Drugs Chapters

This segment of the Immune thrombocytopenia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Immune thrombocytopenia Emerging Drugs
  • Rozanolixizumab (UCB7665): UCB
Rozanolixizumab humanized high-affinity anti-human neonatal Fc receptor (FcRn) monoclonal antibody (IgG4P). By blocking IgG recycling, this subcutaneously infused monoclonal antibody aims to improve the course of immunoglobulin G (IgG)-mediated autoimmune diseases by reducing pathogenic autoantibody levels. Rozanolixizumab, an investigational monoclonal antibody, was granted orphan drug designation for the treatment of ITP by the US Food and Drug Administration on 30 April 2018 and by the European Commission on 11 January 2019. The drug is in Phase III clinical studies for the treatment of idiopathic thrombocytopenic purpura, myasthenia gravis and in Phase II clinical studies for chronic inflammatory demyelinating polyradiculoneuropathy and encephalitis.
  • Efgartigimod: arGEN-X
Efgartigimod is designed as a first-in-class investigational antibody fragment to target the neonatal Fc receptor (FcRn). Efgartigimod is being evaluated for the treatment of patients with severe autoimmune diseases with confirmed presence of pathogenic immunoglobulin G, IgG autoantibodies, where a severe unmet medical need exists. The drug is in registration phase for myasthenia gravis and in Phase III clinical studies for Primary Immune Thrombocytopenia (ITP), chronic inflammatory demyelinating polyradiculoneuropathy, and Pemphigus vulgaris.

Further product details are provided in the report……..

Immune thrombocytopenia: Therapeutic Assessment

This segment of the report provides insights about the different Immune thrombocytopenia drugs segregated based on following parameters that define the scope of the report, such as:
  • Major Players in Immune thrombocytopenia
There are approx. 30+ key companies which are developing the therapies for Immune thrombocytopenia. The companies which have their Immune thrombocytopenia drug candidates in the most advanced stage, i.e. Phase III include, UCB.
  • Phases
DelveInsight’s report covers around 30+ products under different phases of clinical development like
  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration
Immune thrombocytopenia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Oral
  • Parenteral
  • Intravitreal
  • Subretinal
  • Topical
  • Molecule Type
Products have been categorized under various Molecule types such as
  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Immune thrombocytopenia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Immune thrombocytopenia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Immune thrombocytopenia drugs.

Immune thrombocytopenia Report Insights
  • Immune thrombocytopenia Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs
Immune thrombocytopenia Report Assessment
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs
Key Questions

Current Treatment Scenario and Emerging Therapies:
  • How many companies are developing Immune thrombocytopenia drugs?
  • How many Immune thrombocytopenia drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Immune thrombocytopenia?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Immune thrombocytopenia therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Immune thrombocytopenia and their status?
  • What are the key designations that have been granted to the emerging drugs?
Key Players
  • UCB
  • arGEN-X
  • HanAll Biopharma/Immunovant
  • Momenta Pharmaceuticals
  • Principia Biopharma
  • Hutchison MediPharma
  • Cour Pharmaceutical Development
Key Products
  • Rozanolixizumab (UCB7665)
  • Efgartigimod
  • Batoclimab
  • M 254
  • Rilzabrutinib
  • HMPL 523
  • CNP-105

Table of Contents

80 Pages
Introduction
Executive Summary
Immune thrombocytopenia: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Immune thrombocytopenia – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Rozanolixizumab (UCB7665): UCB
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical/Discovery Stage Products
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Immune thrombocytopenia Key Companies
Immune thrombocytopenia Key Products
Immune thrombocytopenia- Unmet Needs
Immune thrombocytopenia- Market Drivers and Barriers
Immune thrombocytopenia- Future Perspectives and Conclusion
Immune thrombocytopenia Analyst Views
Appendix

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us